GlobeNewswire

AC Immune Third Quarter 2026 Financial and Corporate Update
04/11/2026
AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) [...]
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
04/11/2026
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step [...]
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
04/11/2026
Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million [...]
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
04/11/2026
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract [...]
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
04/11/2026
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. [...]
Kane Announces Publication of Real-World Evidence in the International Wound Journal
04/11/2026
Study reports improvements across multiple wound-healing outcomes associated with adjunctive use of revyve® Antimicrobial Wound Gel WINNIPEG, Manitoba, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ( [...]
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
04/11/2026
- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + [...]
Medline Reports Third Quarter and Nine Months 2026 Results
04/11/2026
Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8% Nine months net sales of $ [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
04/11/2026
– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide – – [...]
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
04/11/2026
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular [...]
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
04/11/2026
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
04/11/2026
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will [...]
MediPharm Labs Appoints Greg Hunter as Chief Executive Officer and Director
04/11/2026
Appointment reflects the Board’s confidence in Mr. Hunter’s proven leadership and strengthens MediPharm’s focus on profitable growth, operational excellence and long-term value creation TORONTO, Nov. 04, 2026 (GLOBE [...]
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
04/11/2026
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending [...]
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient [...]
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
04/11/2026
Partnership provides opportunities to further expand Boehringer Ingelheim’s portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs) Agreement reinforces Boehringer Ingelheim’s long-term commitment to [...]
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
04/11/2026
Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties. NXE0033744, an investigational oral EP4 receptor agonist [...]
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
04/11/2026
Tokyo, Japan and Cambridge, UK, 4 November 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, [...]
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
04/11/2026
The FDA recognizes through this designation both the clinical evidence supporting daridorexant and the significant unmet medical need in pediatric insomnia, where no FDA-approved pharmacological treatments are currently [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum